Skip to main content

Advertisement

Table 3 Phase III randomized trials comparing radiochemotherapy plus surgery versus surgery alone

From: Clinical management of gastroesophageal junction tumors: past and recent evidences for the role of radiotherapy in the multidisciplinary approach

  N° Pts Accrual Rate adeno Tumor site Dose/Fx (Gy) Concurrent CT % pCR 3 yy OS % 5 yy OS % Median SVV (mth) Median fup (mth)
        (N° pts RTCT arm) [RTCT+ surg vs. surg alone] [RTCT+ surg vs surg alone] [RTCT+ surg vs surg alone]  
Walsh[43] 113 1990-1995 100% Middle+ Lower Esophagus + Cardias 40/2.7 CDDP + 5Fu 25% (13/52) 32 vs. 6 - 16 vs 11 10 (0.1-59)
         (p=0.01)    
Urba[46] 100 1989-1994 75% Proximal+ Middle + Lower Esophagus + GEJ 45/1.5 (twice daily) CDDP+ 5Fu+ Vimblastine 28% (14/50) 30 vs. 16 - 16.9 vs 17.6 98.4 (72-118.8)
         (p=0.15)    
Burmeister[48] 256 1994-2000 62% Proximal +Middle+ Lower Esophagus 35/2.4 CDDP + 5Fu 16% (16/103) 42 vs. 36 21 vs. 19 22.2 vs. 19.3 65 (0.4-120)
         (p=0.57)    
Tepper[49] 56 1997-2000 75% Toracic Esophagus (below 20 cm)+ GEJ <2cm distal spread in cardia 50.4/1.8 CDDP + 5Fu 40% (10/25) - 39 vs. 16 (p=0.002) 53.8 vs. 21.5 72 (NR)
Van Hagen[50] 366 2004-2008 75% Proximal +Middle+ Lower Esophagus + GEJ 41.2/1.8 Carboplatin + Paclitaxel 29% (47/161) 58 vs. 44 47 vs. 34 49.4 vs. 24 45.4 (25.5-80.9)
         (p=0.003)    
  1. [Pts: patients; Gy: Gray; pCR: pathological complete response; RTCT: radiochemotherapy; yy: years; OS: overall survival; Surg: surgery; SVV: survival; mth: months; Fup: follow-up; CDDP: Cisplatin; 5Fu: 5fluoruracil;].